A longitudinal study of CEACAM1 expression in melanoma disease progression

Oncology Reports

Volumn 33, Issue 3, 2015, Pages 1314-1318

  Zippel, Douglas ^a,b   Barlev, Hani ^a   Ortenberg, Rona ^a   Barshack, Iris ^a,b   Schachter, Jacob ^a,b   Markel, Gal ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

CEACAM1; Immunotherapy; Metastatic melanoma

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; EOSIN; HEMATOXYLIN; CD66 ANTIGENS; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CELL MEMBRANE; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOPLASM; DISEASE ASSOCIATION; DISTANT METASTASIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; LYMPH NODE METASTASIS; MELANOMA; PRIMARY TUMOR; PROTEIN EXPRESSION; BIOSYNTHESIS; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; MELANOCYTE; METABOLISM; PATHOLOGY; PROGNOSIS;

ANTIGENS, CD; BIOMARKERS, TUMOR; CELL ADHESION MOLECULES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LONGITUDINAL STUDIES; LYMPHATIC METASTASIS; MELANOCYTES; MELANOMA; PROGNOSIS;

EID: 84921665150     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3703     Document Type: Article

References (23)

1. Sapoznik S, Hammer O, Ortenberg R, et al: Novel anti-melanoma immunotherapies: Disarming tumor escape mechanisms. Clin Dev Immunol 2012:818214, 2012.
2. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010.
3. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011.
4. Hamid O, Robert C, Daud A, et al: Safety and tumor response with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013.
5. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012.
6. Ortenberg R, Sapir Y, Raz L et al: Novel immunotherapy for malignant melanoma with a monoclonal antibody that block CEACAM1 homophillic interactions. Mol Cancer Ther 6:1300-1310, 2012.
7. Gray-Owen SD and Blumberg RS: CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 6:433-446, 2006.
8. Dango S, Sienel W, Schreiber M, et al: Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is associated with increased angiogenic potential in non small cell lung cancer. Lung Cancer 60:426-433, 2008.
9. Zhou CJ, Liu B, Zhu KX, et al: The different expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and possible roles in gastric carcinoma. Pathol Res Pract 205:483-489, 2009.
10. Ortenberg R, Galore-Haskel G, Greenberg I, et al: CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia 16:451-460, 2014.
11. Thies A, Moll I, Berger J, et al: CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 20:2530-2536, 2002.
12. Laack E, Nikbakht H, Peters A, et al: Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol 20:4279-4284, 2002.
13. Sienel W, Dango S, Woelfle U, et al: Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res 9:2260-2266, 2003.
14. Muller MM, Klaile E, Vorontsova O, et al: Homophillic adhesion and CEACAM1-S regulate dimerization of CEACAM1-L and recruitment of SHP-2 and c-SR C. J Cell Biol 187:569-581, 2009.
15. Chen Z, Chen L, Qiao SW, et al: Carcinoembryonic antigenrelated cell adhesion molecule 1 inhibits proximal TCR signaling by targeting ZAP-70. J Immunol 180:6085-6093, 2008.
16. Markel G, Leiberman N, Katz G, et al: CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 168:2803-2810, 2002.
17. Markel G, Wolf D, Hanna J, Gazit R, et al: Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 110:943-953, 2002.
18. Markel G, Seidman R, Stern N, et al: Inhibition of human tumorinfiltrating lymphocyte effector functions by the homophillic carcinoembryonic cell adhesion molecules 1 interactions. J Immunol 177:6062-6071, 2006.
19. Markel G, Ortenberg R, Seidman R, et al: Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immmunother 59:215-230, 2010.
20. Ebrahimnejad A, Streichert T, Nollau P, et al: CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol 165:1781-1787, 2004.
21. Gamblicher T, Grothe S, Rotterdam S, et al: Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions. Am J Clin Pathol 131:782-787, 2009.
22. Markel G, Seidman R, Cohen Y, et al: Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 126:186-200, 2009.
23. Eggermont AM, Chiarion-Seleni V, Grob JJ, et al: Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. Presented at the 2014 Annual Meeting of the American Society of Clinical Oncology; May 30-June 2, 2014; Chicago, IL. J Clin Oncol 32(15 Suppl): LBA9008, 2014.